R21 in Matrix-M adjuvant in UK malaria-naive adult men and non-pregnant women aged 18-45 years: an open-label, partially blinded, phase 1-2a controlled human malaria infection study.

Saved in:
Bibliographic Details
Title: R21 in Matrix-M adjuvant in UK malaria-naive adult men and non-pregnant women aged 18-45 years: an open-label, partially blinded, phase 1-2a controlled human malaria infection study.
Authors: Venkatraman N; Jenner Institute, University of Oxford and the NIHR Oxford Biomedical Research Centre, Oxford, UK; Centre for Clinical Vaccinology and Tropical Medicine, Churchill Hospital, Oxford, UK., Silman D; Jenner Institute, University of Oxford and the NIHR Oxford Biomedical Research Centre, Oxford, UK; Centre for Clinical Vaccinology and Tropical Medicine, Churchill Hospital, Oxford, UK., Bellamy D; Jenner Institute, University of Oxford and the NIHR Oxford Biomedical Research Centre, Oxford, UK., Stockdale L; Jenner Institute, University of Oxford and the NIHR Oxford Biomedical Research Centre, Oxford, UK., Bowyer G; Jenner Institute, University of Oxford and the NIHR Oxford Biomedical Research Centre, Oxford, UK., Edwards NJ; Jenner Institute, University of Oxford and the NIHR Oxford Biomedical Research Centre, Oxford, UK., Griffiths O; Centre for Clinical Vaccinology and Tropical Medicine, Churchill Hospital, Oxford, UK., Lopez FR; Centre for Clinical Vaccinology and Tropical Medicine, Churchill Hospital, Oxford, UK., Powlson J; Jenner Institute, University of Oxford and the NIHR Oxford Biomedical Research Centre, Oxford, UK., Mair C; Jenner Institute, University of Oxford and the NIHR Oxford Biomedical Research Centre, Oxford, UK., Folegatti PM; Jenner Institute, University of Oxford and the NIHR Oxford Biomedical Research Centre, Oxford, UK; Centre for Clinical Vaccinology and Tropical Medicine, Churchill Hospital, Oxford, UK., Datoo MS; Jenner Institute, University of Oxford and the NIHR Oxford Biomedical Research Centre, Oxford, UK; Centre for Clinical Vaccinology and Tropical Medicine, Churchill Hospital, Oxford, UK., Morter R; Jenner Institute, University of Oxford and the NIHR Oxford Biomedical Research Centre, Oxford, UK., Minassian AM; Jenner Institute, University of Oxford and the NIHR Oxford Biomedical Research Centre, Oxford, UK; Centre for Clinical Vaccinology and Tropical Medicine, Churchill Hospital, Oxford, UK; Department of Biochemistry, University of Oxford, Oxford, UK., Poulton I; Jenner Institute, University of Oxford and the NIHR Oxford Biomedical Research Centre, Oxford, UK; Centre for Clinical Vaccinology and Tropical Medicine, Churchill Hospital, Oxford, UK., Collins KA; Jenner Institute, University of Oxford and the NIHR Oxford Biomedical Research Centre, Oxford, UK., Brod F; Jenner Institute, University of Oxford and the NIHR Oxford Biomedical Research Centre, Oxford, UK., Angell-Manning P; Clinical Biomanufacturing Facility, University of Oxford, Oxford, UK., Berrie E; Clinical Biomanufacturing Facility, University of Oxford, Oxford, UK., Brendish N; NIHR Southampton Clinical Research Facility and Biomedical Research Centre, University Hospital Southampton NHS Foundation Trust, Southampton, UK; Faculty of Medicine and Institute for Life Sciences, University of Southampton, Southampton, UK., Glenn G; Novavax, Gaithersburg, MD, USA., Fries L; Novavax, Gaithersburg, MD, USA., Baum J; School of Biomedical Sciences, UNSW Sydney, Sydney, NSW, Australia., Blagborough AM; Department of Pathology, University of Cambridge, Cambridge, UK., Roberts R; Jenner Institute, University of Oxford and the NIHR Oxford Biomedical Research Centre, Oxford, UK; Centre for Clinical Vaccinology and Tropical Medicine, Churchill Hospital, Oxford, UK., Lawrie AM; Jenner Institute, University of Oxford and the NIHR Oxford Biomedical Research Centre, Oxford, UK; Centre for Clinical Vaccinology and Tropical Medicine, Churchill Hospital, Oxford, UK., Angus B; Centre for Clinical Vaccinology and Tropical Medicine, Churchill Hospital, Oxford, UK., Lewis DJM; NIHR/Wellcome Trust Imperial Clinical Research Facility, Imperial Centre for Translational and Experimental Medicine, London, UK., Faust SN; NIHR Southampton Clinical Research Facility and Biomedical Research Centre, University Hospital Southampton NHS Foundation Trust, Southampton, UK; Faculty of Medicine and Institute for Life Sciences, University of Southampton, Southampton, UK., Ewer KJ; Jenner Institute, University of Oxford and the NIHR Oxford Biomedical Research Centre, Oxford, UK. Electronic address: katie.j.ewer@gsk.com., Hill AVS; Jenner Institute, University of Oxford and the NIHR Oxford Biomedical Research Centre, Oxford, UK.
Source: The Lancet. Microbe [Lancet Microbe] 2025 Mar; Vol. 6 (3), pp. 100867. Date of Electronic Publication: 2025 Jan 10.
Publication Type: Journal Article; Clinical Trial, Phase I; Clinical Trial, Phase II
Journal Info: Publisher: Elsevier Ltd Country of Publication: England NLM ID: 101769019 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2666-5247 (Electronic) Linking ISSN: 26665247 NLM ISO Abbreviation: Lancet Microbe Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:2666-5247
DOI:10.1016/S2666-5247(24)00083-1